Losing weight in midlife may have a hidden brain cost
December 28, 2025 / midlife weight loss / brain inflammation risk / cognitive decline connection / neurodegenerative disease link / metabolic health tradeoff
Midlife weight loss may worsen brain inflammation, particularly in areas regulating appetite and energy, potentially increasing the risk for cognitive decline and neurodegenerative diseases, despite metabolic improvements observed in animal models.
Effect of therapeutic lifestyle change on metabolic syndrome in adults: a randomized controlled trial
December 29, 2025 / metabolic syndrome treatment / lifestyle intervention benefits / cardio-metabolic risk reduction / non-drug therapy MetS / diet exercise blood pressure
A 3-month therapeutic lifestyle change (TLC) program significantly reduced metabolic syndrome prevalence and improved weight, blood pressure, lipids, and glucose in adults. TLC may offer a cost-effective, non-pharmacological approach to managing cardio-metabolic risk factors.
Obesity link exposed: How refined oils may be sabotaging your health
December 23, 2025 / refined oils obesity / avocado oil benefits / metabolic health inflammation / healthy fat cooking / fatty liver prevention
Refined vegetable oils may worsen obesity and metabolic disorders by promoting inflammation and oxidative stress. In contrast, avocado oil’s heat stability and healthy fats support metabolic health, improving insulin response, cholesterol, and reducing risk of fatty liver disease.
Long-term physical activity protects against metabolic syndrome, suggests study
December 29, 2025 / metabolic syndrome prevention / lifelong physical activity / exercise health benefits / muscle strengthening metabolism / midlife fitness impact
A 34-year Finnish study found that consistent physical activity—especially muscle-strengthening exercises—significantly reduces the risk of metabolic syndrome in late adulthood, while starting exercise later in life still provides notable metabolic health benefits.
Lupin and Gan & Lee enter exclusive licensing deal for novel GLP-1 receptor agonist
December 29, 2025 / GLP-1 therapy India / diabetes obesity treatment / Bofanglutide weight loss / metabolic disease drug / Lupin Gan & Lee
Lupin has secured exclusive rights to Bofanglutide, a novel GLP-1 receptor agonist for diabetes and obesity, offering fortnightly dosing with efficacy and safety comparable or superior to weekly GLP-1 treatments, addressing India’s growing metabolic health burden.
GLP-1 Use Rising Among People With MASH, Mild Cirrhosis
December 29, 2025 / GLP-1 MASH treatment / fatty liver diabetes / semaglutide liver fibrosis / obesity cirrhosis drug / Wegovy liver disease
GLP-1 receptor agonist use is rising among patients with MASH and compensated cirrhosis, showing promise in managing comorbid obesity and diabetes. Recent data and FDA approvals support incorporating GLP-1s into future treatment strategies and clinical trial designs.
Resveratrol’s Impact on Weight and Hormones Reviewed
December 27, 2025 / resveratrol weight loss / leptin adiponectin obesity / polyphenol metabolism effects / obesity supplement research / gut microbiome resveratrol
A 2025 meta-analysis found that resveratrol supplementation does not significantly impact weight, BMI, or key hormones like adiponectin and leptin in overweight individuals, highlighting variability in results and the need for more rigorous, standardized clinical trials.
The Trillion-Dollar Apothecary: Inside Eli Lilly’s Era of Metabolic Dominance
December 29, 2025 / tirzepatide / obesity treatment / GLP-1 drugs / Eli Lilly pipeline / Alzheimer’s drug Kisunla
Eli Lilly’s $1 trillion valuation is driven by tirzepatide’s success in diabetes and obesity and Kisunla’s advancement in Alzheimer’s. Its metabolic dominance reflects unmatched clinical efficacy, manufacturing strength, and a robust pipeline of next-generation therapies.
Obesity research: new findings challenge established fat metabolism understanding
December 26, 2025 / HSL protein / fat metabolism / obesity research / adipocyte regulation / metabolic disease
New research reveals that the fat-burning enzyme HSL also regulates gene activity in fat cells, reshaping our understanding of obesity. This dual role may explain conditions like lipodystrophy and opens new avenues for metabolic disease treatment.
How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson
December 23, 2024 / GLP-1 agonists / obesity treatment / metabolic health / appetite regulation / weight loss therapy
GLP-1 agonists aid weight loss by regulating insulin, appetite, and brain signals. Beyond obesity, they’re being explored for broader metabolic benefits. Sustainable results require clinical oversight and long-term lifestyle support.
Manipal Hospital Sarjapur Road Expands Clinical Expertise With Five New Specialist Appointments
December 26, 2025 / urology specialist / gastroenterology expert / pulmonology care / minimally invasive surgery / internal medicine Bengaluru
Manipal Hospital Sarjapur Road expands its multidisciplinary care with five new specialists in urology, internal medicine, pulmonology, gastroenterology, and surgery, enhancing its capabilities in advanced, minimally invasive, and preventive healthcare services for the Bengaluru region.
MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement
December 22, 2025 / cardiometabolic diseases / biotech compliance / Nasdaq listing update / clinical-stage company / MetaVia stock news
MetaVia Inc., a biotech firm targeting cardiometabolic diseases, has regained compliance with Nasdaq’s minimum bid price requirement, ensuring continued listing on the Nasdaq Capital Market following formal notification received on December 19, 2025.
Eating takeout food too often may increase cardiovascular disease risk
December 27, 2025 / takeout food risk / inflammation heart disease / Dietary Inflammatory Index / cardiometabolic health / cardiovascular disease diet
A study of over 8,500 adults found that frequent takeout food consumption is linked to increased systemic inflammation and worsened cardiometabolic markers, suggesting a potential elevated risk for cardiovascular disease through diet-induced inflammation.
MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement
December 22, 2025 / MetaVia compliance / Nasdaq listing / cardiometabolic biotech / stock market biotech / minimum bid price
MetaVia Inc., a biotech company targeting cardiometabolic diseases, has regained compliance with Nasdaq’s minimum bid price requirement, securing its continued listing on the Nasdaq Capital Market as of December 19, 2025.
Cardiorenal-Metabolic Disease in Focus: Applying the CKM Framework in Diabetes Practice
December 25, 2025 / CKM framework / diabetes care / cardiorenal metabolic / ADA guidelines / GLP-1 SGLT2 therapy
The CKM framework integrates cardiovascular, kidney, and metabolic care in diabetes management, promoting comprehensive risk assessment and therapy selection. ADA 2025 guidelines support this unified approach to improve outcomes beyond glycemic control.
A Tiny Gut Molecule Might Cut Type 2 Diabetes Risk, And Scientists Say It Flips Everything We Thought We Knew
December 24, 2025 / TMA molecule / type 2 diabetes / insulin resistance / gut microbiome / inflammation prevention
New research reveals that the gut-derived molecule TMA may protect against inflammation and insulin resistance, challenging its prior association with disease and suggesting a potential role in preventing type 2 diabetes linked to high-fat diets.
Association of surrogate indices of insulin resistance with hypertension: a cross-sectional analysis from PERSIAN Dena cohort study (PDCS)
December 29, 2025 / insulin resistance / hypertension risk / TyG-BMI index / metabolic screening / sex-specific analysis
This study found that insulin resistance indices, especially TyG-BMI, are significantly associated with hypertension risk, particularly in men, suggesting these surrogate markers could support early hypertension screening in population-specific, sex-sensitive strategies.
Holistic eHealth Intervention for Metabolic Syndrome in Seniors
December 29, 2025 / metabolic syndrome / eHealth intervention / older adults / holistic care / psychosomatic symptoms
A holistic eHealth intervention for seniors with metabolic syndrome and psychosomatic symptoms aims to improve health through lifestyle changes, mental well-being, and technology-based care. The randomized trial will evaluate its effectiveness in promoting healthier aging.
Breaking down silos of care to optimize management of cardiovascular-kidney-metabolic syndrome
December 29, 2025 / CKM syndrome / cardiovascular kidney metabolic / integrated care / cardiometabolic risk / pharmacist role
The cardiovascular-kidney-metabolic (CKM) syndrome framework highlights the interconnected nature of obesity, diabetes, hypertension, CKD, and cardiovascular disease, emphasizing integrated, team-based care—including pharmacist involvement—to improve outcomes for nearly one-third of U.S. adults.
MASLD Raises Liver Cancer Risk After Hepatitis C Cure
December 29, 2025 / MASLD liver cancer / hepatitis C cure / hepatocellular carcinoma risk / fatty liver disease / post-HCV surveillance
Post–hepatitis C cure, patients with MASLD and moderate-to-severe fibrosis remain at elevated hepatocellular carcinoma risk. Data show fatty liver disease independently drives liver cancer incidence, underscoring the need for ongoing risk stratification and surveillance despite viral clearance.